Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis
Introduction: Scalp psoriasis adversely affects patients’ lives and is often resistant to treatment; however, it has not been a major focus of a clinical study. This analysis assessed the effect of secukinumab on patient-reported outcomes (PRO) of scalp psoriasis. Methods: A randomized, double-blind...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-11-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2017.1329502 |
| _version_ | 1797683759729868800 |
|---|---|
| author | Steven R. Feldman Lawrence Green Alexa B. Kimball Kimberly Siu Yang Zhao Vivian Herrera Judit Nyirady Andrew F. Alexis |
| author_facet | Steven R. Feldman Lawrence Green Alexa B. Kimball Kimberly Siu Yang Zhao Vivian Herrera Judit Nyirady Andrew F. Alexis |
| author_sort | Steven R. Feldman |
| collection | DOAJ |
| description | Introduction: Scalp psoriasis adversely affects patients’ lives and is often resistant to treatment; however, it has not been a major focus of a clinical study. This analysis assessed the effect of secukinumab on patient-reported outcomes (PRO) of scalp psoriasis. Methods: A randomized, double-blind, placebo-controlled, multicenter study was conducted in 102 adult patients with moderate-to-severe scalp psoriasis. Patients were randomized 1:1 to secukinumab 300 mg or placebo. Patients rated their scalp-related pain, itching and scaling using a 0–10 numeric rating scale (higher scores indicate greater severity). Scalp dermatitis-related quality of life (QOL) was assessed at baseline and then every 4 weeks using the Scalpdex. Analysis of covariance models examined PRO effect up to 12 weeks. Results: Baseline scalp pain, itching and scaling mean (SD) values were 3.1 (3.00), 6.7 (2.60) and 7.3 (2.02) and similar for both treatment groups. At week 12, patients treated with secukinumab reported greater reduction in scalp pain (−1.98 vs. 0.61), itching (−4.07 vs. −0.04) and scaling (−5.76 vs. −0.95) as well as greater improvements in Scalpdex total scores (−39.62 vs. −7.91) compared with placebo (all p < .001). Discussion/Conclusions: Secukinumab in moderate-to-severe scalp psoriasis reduces scalp pain, itching, and scaling and improves patients’ QOL. |
| first_indexed | 2024-03-12T00:19:29Z |
| format | Article |
| id | doaj.art-b5e70c2a87a94e739fe767c40d06d7d5 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:19:29Z |
| publishDate | 2017-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-b5e70c2a87a94e739fe767c40d06d7d52023-09-15T14:08:30ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532017-11-0128871672110.1080/09546634.2017.13295021329502Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasisSteven R. Feldman0Lawrence Green1Alexa B. Kimball2Kimberly Siu3Yang Zhao4Vivian Herrera5Judit Nyirady6Andrew F. Alexis7Wake Forest Baptist Medical CenterGeorge Washington University School of MedicineHarvard Medical School, Beth Israel Deaconess Medical CenterNovartis Pharmaceuticals CorporationNovartis Pharmaceuticals CorporationNovartis Pharmaceuticals CorporationNovartis Pharmaceuticals CorporationIcahn School of Medicine at Mount Sinai and Mount Sinai St. Luke'sIntroduction: Scalp psoriasis adversely affects patients’ lives and is often resistant to treatment; however, it has not been a major focus of a clinical study. This analysis assessed the effect of secukinumab on patient-reported outcomes (PRO) of scalp psoriasis. Methods: A randomized, double-blind, placebo-controlled, multicenter study was conducted in 102 adult patients with moderate-to-severe scalp psoriasis. Patients were randomized 1:1 to secukinumab 300 mg or placebo. Patients rated their scalp-related pain, itching and scaling using a 0–10 numeric rating scale (higher scores indicate greater severity). Scalp dermatitis-related quality of life (QOL) was assessed at baseline and then every 4 weeks using the Scalpdex. Analysis of covariance models examined PRO effect up to 12 weeks. Results: Baseline scalp pain, itching and scaling mean (SD) values were 3.1 (3.00), 6.7 (2.60) and 7.3 (2.02) and similar for both treatment groups. At week 12, patients treated with secukinumab reported greater reduction in scalp pain (−1.98 vs. 0.61), itching (−4.07 vs. −0.04) and scaling (−5.76 vs. −0.95) as well as greater improvements in Scalpdex total scores (−39.62 vs. −7.91) compared with placebo (all p < .001). Discussion/Conclusions: Secukinumab in moderate-to-severe scalp psoriasis reduces scalp pain, itching, and scaling and improves patients’ QOL.http://dx.doi.org/10.1080/09546634.2017.1329502scalp psoriasissecukinumabsymptomspatient-reported outcomesitchingpainscaling |
| spellingShingle | Steven R. Feldman Lawrence Green Alexa B. Kimball Kimberly Siu Yang Zhao Vivian Herrera Judit Nyirady Andrew F. Alexis Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis Journal of Dermatological Treatment scalp psoriasis secukinumab symptoms patient-reported outcomes itching pain scaling |
| title | Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis |
| title_full | Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis |
| title_fullStr | Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis |
| title_full_unstemmed | Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis |
| title_short | Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis |
| title_sort | secukinumab improves scalp pain itching scaling and quality of life in patients with moderate to severe scalp psoriasis |
| topic | scalp psoriasis secukinumab symptoms patient-reported outcomes itching pain scaling |
| url | http://dx.doi.org/10.1080/09546634.2017.1329502 |
| work_keys_str_mv | AT stevenrfeldman secukinumabimprovesscalppainitchingscalingandqualityoflifeinpatientswithmoderatetoseverescalppsoriasis AT lawrencegreen secukinumabimprovesscalppainitchingscalingandqualityoflifeinpatientswithmoderatetoseverescalppsoriasis AT alexabkimball secukinumabimprovesscalppainitchingscalingandqualityoflifeinpatientswithmoderatetoseverescalppsoriasis AT kimberlysiu secukinumabimprovesscalppainitchingscalingandqualityoflifeinpatientswithmoderatetoseverescalppsoriasis AT yangzhao secukinumabimprovesscalppainitchingscalingandqualityoflifeinpatientswithmoderatetoseverescalppsoriasis AT vivianherrera secukinumabimprovesscalppainitchingscalingandqualityoflifeinpatientswithmoderatetoseverescalppsoriasis AT juditnyirady secukinumabimprovesscalppainitchingscalingandqualityoflifeinpatientswithmoderatetoseverescalppsoriasis AT andrewfalexis secukinumabimprovesscalppainitchingscalingandqualityoflifeinpatientswithmoderatetoseverescalppsoriasis |